Pharmacoeconomic evaluation of Bacillus Calmette-Guérin for post-TUR-BT perfusion therapy in patients with intermediate-to high-risk non-muscle invasive bladder cancer in China
- VernacularTitle:卡介苗用于我国中高危非肌层浸润性膀胱癌患者TUR-BT术后灌注治疗的药物经济学评价
- Author:
Zhicheng SU
1
;
Lu LI
2
;
Qiang YAO
1
;
Cairong ZHU
1
;
Tao JIA
3
Author Information
1. Department of Epidemiology and Health Statistics，West China School of Public Health/West China Fourth Hospital，Sichuan University，Chengdu 610041，China
2. Chengdu Rongsheng Pharmaceuticals Co.，Ltd.，Chengdu 610093，China
3. China National Biotech Co.，Ltd.，Beijing 100011，China
- Publication Type:Journal Article
- Keywords:
Bacillus Calmette-Guérin;
non-muscle-invasive
- From:
China Pharmacy
2024;35(22):2773-2778
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE To evaluate the cost-effectiveness of using Bacillus Calmette-Guérin （BCG） versus epirubicin for intravesical perfusion after transurethral resection of bladder tumor （TUR-BT） in patients with intermediate- to high-risk non-muscle- invasive bladder cancer （NMIBC）. METHODS From the perspective of China’s health system， a Markov cohort model was constructed based on the ChiCTR-IIR-16008357 study. Quality-adjusted life years （QALYs） were used as the health outcome measure， with the willingness-to-pay（WTP） threshold set at one time the per capita gross domestic product of China in 2023 （89 358 yuan/QALY）. A cost-utility analysis was used to compare the incremental cost-effectiveness ratio （ICER） of the BCG regimen relative to the epirubicin regimen for intravesical perfusion after TUR-BT in patients with intermediate- to high-risk NMIBC in China. In addition， sensitivity analysis was performed. RESULTS The incremental cost of the BCG regimen compared to the epirubicin regimen was 34 309.51 yuan， with an incremental utility of 0.800 QALYs， resulting in an ICER of 42 871.33 yuan/QALY， which is below the WTP threshold. When the WTP threshold was 89 358 yuan/QALY， the probability that the BCG regimen would be acceptable was 77.70% in the probabilistic sensitivity analysis， higher than that of the epirubicin regimen， and the acceptability of the BCG regimen increased with increasing in the WTP threshold. CONCLUSIONS When the WTP threshold was set at one time the per capita gross domestic product of China in 2023， compared to epirubicin， BCG used for intravesical perfusion after TUR-BT in patients with intermediate- to high-risk NMIBC demonstrated better cost-effectiveness.
